UnknownNot Applicable

Impact of Sodium-glucose Cotransporter 2 Inhibitors on Post-operative Atrial Fibrillation in Cardiothoracic Surgery

Qatar3,280 participantsStarted 2023-10-01

Plain-language summary

SGLT2 inhibitors are oral anti-diabetic medications that were found to improve cardiorenal outcomes in patients with type 2 diabetes mellitus (DM), chronic heart failure with reduced and preserved ejection fraction, and chronic kidney disease. Recent evidence suggested that the use of SGLT2 inhibitors resulted in a significant reduction in atrial fibrillation (AF) over a mean follow-up duration of 2.6 years. Given the possible AF protective benefit with SGLT2 inhibitors use.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults \> 18 years undergoing cardiothoracic surgery, including CABG, mechanical valve replacement, bioprosthetic valve replacement, or valve repair. * Use of SGLT2 inhibitors for a minimum of 1 week prior to surgery regardless of DM status. * Resumption of SGLT2 inhibitor after stepping down from the intensive care unit. Exclusion Criteria: * Known AF on anticoagulation. * Chronic kidney disease with CrCl \< 25 mL/min.

What they're measuring

Incidence of post-operative atrial fibrillation (POAF)

Timeframe: 1 month

Trial details

NCT IDNCT06251453

SponsorHamad Medical Corporation

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-12-01

Contact for this trial

Alaa Rahhal, Msc

55712353 ARahhal1@hamad.qa

View on ClinicalTrials.gov More Atrial Fibrillation trials